This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Roberts, W. G. Articles by Ung, E. Search for Related Content PubMed PubMed Citation Articles by Roberts, W. G. Articles by Ung, E.

Antiangiogenic and Antitumor Activity of a Selective PDGFR Tyrosine Kinase Inhibitor, CP-673,451

Pfizer Oncology, Pfizer Global Research and Development, Groton, Connecticut

Requests for reprints: W. Gregory Roberts, Pfizer Oncology, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340. Phone: 860-441-8478; Fax: 860-715-2382; E-mail: robertswg{at}groton.pfizer.com.

CP-673,451 is a potent inhibitor of platelet-derived growth factor ß-receptor (PDGFR-ß) kinase- and PDGF-BB-stimulated autophosphorylation of PDGFR-ß in cells (IC₅₀ = 1 nmol/L) being more than 450-fold selective for PDGFR-ß versus other angiogenic receptors (e.g., vascular endothelial growth factor receptor 2, TIE-2, and fibroblast growth factor receptor 2). Multiple models have been used to evaluate in vivo activity of CP-673,451 and to understand the pharmacology of PDGFR-ß inhibition and the effect on tumor growth. These models include an ex vivo measure of PDGFR-ß phosphorylation in glioblastoma tumors, a sponge model to measure inhibition of angiogenesis, and multiple models of tumor growth inhibition. Inhibition of PDGFR-ß phosphorylation in tumors correlates with plasma and tumor levels of CP-673,451. A dose of 33 mg/kg was adequate to provide >50% inhibition of receptor for 4 hours corresponding to an EC₅₀ of 120 ng/mL in plasma at C_max. In a sponge angiogenesis model, CP-673,451 inhibited 70% of PDGF-BB-stimulated angiogenesis at a dose of 3 mg/kg (q.d. x 5, p.o., corresponding to 5.5 ng/mL at C_max). The compound did not inhibit vascular endothelial growth factor- or basic fibroblast growth factor-induced angiogenesis at concentrations which inhibited tumor growth. The antitumor efficacy of CP-673,451 was evaluated in a number of human tumor xenografts grown s.c. in athymic mice, including H460 human lung carcinoma, Colo205 and LS174T human colon carcinomas, and U87MG human glioblastoma multiforme. Once-daily p.o. x 10 days dosing routinely inhibited tumor growth (ED₅₀ 33 mg/kg). These data show that CP-673,451 is a pharmacologically selective PDGFR inhibitor, inhibits tumor PDGFR-ß phosphorylation, selectively inhibits PDGF-BB-stimulated angiogenesis in vivo, and causes significant tumor growth inhibition in multiple human xenograft models.

Key Words: Angiogenesis • platelet-derived growth factor ß • platelet-derived growth factor • vascular endothelial growth factor • CP-673,451 • tyrosine kinase receptors • tyrosine kinase inhibitor • in vivo pharmacology

This article has been cited by other articles:

				D. D. Hu-Lowe, H. Y. Zou, M. L. Grazzini, M. E. Hallin, G. R. Wickman, K. Amundson, J. H. Chen, D. A. Rewolinski, S. Yamazaki, E. Y. Wu, et al. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Clin. Cancer Res., November 15, 2008; 14(22): 7272 - 7283. [Abstract] [Full Text] [PDF]

				Q. Zhong, Y.-J. Wen, H.-S. Yang, H. Luo, A.-F. Fu, F. Yang, L.-J. Chen, X. Chen, X.-R. Qi, H.-G. Lin, et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice Ann. Onc., September 1, 2008; 19(9): 1584 - 1591. [Abstract] [Full Text] [PDF]

				E. I. Fomchenko and E. C. Holland Mouse models of brain tumors and their applications in preclinical trials. Clin. Cancer Res., September 15, 2006; 12(18): 5288 - 5297. [Abstract] [Full Text] [PDF]

				R. H. Alvarez, H. M. Kantarjian, and J. E. Cortes Biology of Platelet-Derived Growth Factor and Its Involvement in Disease Mayo Clin. Proc., September 1, 2006; 81(9): 1241 - 1257. [Abstract] [Full Text] [PDF]

				S. Patyna, A. D. Laird, D. B. Mendel, A.-M. O'Farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, et al. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol. Cancer Ther., July 1, 2006; 5(7): 1774 - 1782. [Abstract] [Full Text] [PDF]

				D. A. Reardon and P. Y. Wen Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist, February 1, 2006; 11(2): 152 - 164. [Abstract] [Full Text] [PDF]